PFS With Ibrutinib Combo is ‘Promising’ in Chronic Lymphocytic Leukemia
Ibrutinib plus venetoclax appears to be effective across the overall chronic lymphocytic leukemia population in the CAPTIVATE study, although progression-free survival is shorter for those with TP53 mutations.
During the 2023 American Society of Hematology (ASH) Annual Meeting, Paolo Ghia, MD, PhD, spoke with CancerNetwork® about how combining ibrutinib (Imbruvica) with venetoclax (Venclexta) yielded positive progression-free survival (PFS) data in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma based on up to 5 years of follow-up data from the phase 2 CAPTIVATE study.
According to Ghia, a full professor in Medical Oncology at Università Vita-Salute San Raffaele, and the deputy chairman of the Division of Experimental Oncology at IRCCS Ospedale San Raffaele, Milano, fixed-duration therapy with ibrutinib plus venetoclax appeared to be effective across the general study population. However, the PFS rate was lower for those with TP53-mutated disease; he suggested that further follow up may be necessary for this patient subgroup.
The 54-month PFS rate was 70% (95% CI, 62%-77%) in the fixed-duration cohort (n = 159) and 45% (95% CI, 25%-64%) in those with a TP53 mutation or 17p deletion (n = 27). Additionally, investigators reported corresponding rates of 68% (95% CI, 50%-80%) in patients with unmutated IGHV (n = 40), 64% (95% CI, 30%-85%) in those with an 11q deletion (n = 11), and 60% (95% CI, 41%-75%) in a group of patients with complex karyotype.
Transcript:
We also presented the data about progression-free survival. Now, of course, we all want to know how long patients remain off therapy and whether they [will] progress. After a fixed-duration treatment and 54 months of follow up, 70% of the patients are still responding; patients with unmutated [IGHV], 68% are still responding. Patients with TP53 aberrations are losing a little bit of response earlier; still, 45% of them are responding after 54 months of follow up.
These are very promising data. The fixed-duration treatment with ibrutinib plus venetoclax appears to be very effective in virtually all patients. Maybe we have to evaluate the effect [of the combination] a little bit longer in patients with TP53 aberrations.
Reference
Ghia P, Wierda WG, Barr PM, et al. Relapse after first-line fixed duration ibrutinib + venetoclax: high response rates to ibrutinib retreatment and absence of BTK Mutations in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with up to 5 years of follow-up in the phase 2 Captivate study. Blood. 2023;142(suppl 1):633. doi:10.1182/blood-2023-187128
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
